Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children Ages 4 to 17 Years (RAMSES)
Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children Ages 4 to 17 Years (RAMSES)
This is a multicenter, randomized, double-blind, placebo-controlled safety study of AR101 using the characterized oral desensitization immunotherapy (CODITâ„¢) regimen in peanut-allergic children.
The primary objective is to assess the safety and tolerability of AR101 when used in a CODITâ„¢ regimen for approximately 6 months in peanut-allergic children children aged 4 to 17 years, inclusive.
Key Inclusion Criteria:
Key Exclusion Criteria:
Los Angeles, California 90027, United States
Mountain View, California 94040, United States
San Jose, California 95117, United States
Tampa, Florida 33613, United States
Chapel Hill, North Carolina 27599, United States
Oklahoma City, Oklahoma 73131, United States
Philadelphia, Pennsylvania 19104, United States
Austin, Texas 78723, United States